Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

19 Oct 2017 09:20

RNS Number : 0668U
Hutchison China Meditech Limited
19 October 2017
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hutchison China MediTech Limited

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

Slater Investments Limited

4. Full name of shareholder(s) (if different from 3.):iv

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

18 October 2017

6. Date on which issuer notified:

18 October 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Below 3%

      
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

KYG4672N1016

1,824,926

1,824,926

232,538

232,538

 1,581,388

0.38%

2.60%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,813,926

2.98%

                
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

14. Contact name:

Ralph Baber

15. Contact telephone number:

+ 44 20 7220 9460

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMLBPTMBBBMTR
Date   Source Headline
24th Mar 20177:00 amRNSAppointment of Director
21st Mar 201710:08 amRNSChi-Med to host R&D Briefings
20th Mar 20178:04 amRNSDirectors' Share Dealing
16th Mar 201711:25 amRNSGrant of Awards under Long Term Incentive Plan
13th Mar 20177:00 amRNSPublication of Form 20-F
13th Mar 20177:00 amRNSFinal Results
10th Mar 20178:11 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
10th Mar 20177:18 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
7th Mar 201711:49 amEQSEdison issues update on Hutchison China Meditech (HCM)
3rd Mar 20177:00 amRNSPositive Fruquintinib Pivotal Phase III Results
28th Feb 201710:20 amRNSChange of Directors
20th Feb 20177:00 amRNSStart of Phase II Savolitinib PSC trial in China
14th Feb 20177:07 amRNSInitiates Phase I of Novel FGFR Inhibitor HMPL-453
14th Feb 20177:00 amRNSSavolitinib PRCC Results Presentation at ASCO GU
6th Feb 20177:00 amRNSChi-Med to Announce 2016 Final Results
1st Feb 20177:00 amRNSChange of Directors
16th Jan 201710:48 amRNSChange of Directors
16th Jan 201710:11 amRNSChange of Directors
16th Jan 20177:30 amRNSFruquintinib Phase I/II Clinical Data at ASCO GI
16th Jan 20177:29 amRNSSulfatinib Phase II Study in 2nd Line BTC in China
16th Jan 20177:16 amRNSFruquintinib Combination Study in 1st-Line NSCLC
10th Jan 20177:00 amRNSChi-Med Initiates HMPL-523 Clinical Trials
30th Dec 20169:11 amRNSTotal Voting Rights
29th Dec 20167:40 amRNSBlocklisting Six Monthly Return
20th Dec 20167:18 amRNSDirector's Share Dealing
14th Dec 20167:14 amRNSDirector's Share Dealing
6th Dec 20167:00 amRNSHMPL-523 Pre-clinical Data Presented at ASH
30th Nov 20167:51 amRNSExercise of Share Options
30th Nov 20167:48 amRNSTotal Voting Rights
23rd Nov 20167:34 amRNSDirector's Share Dealing
23rd Nov 20167:30 amRNSChi-Med to Present Data at the 17th WCLC
23rd Nov 20167:08 amRNSChi-Med to Present Data at the at the 17th WCLC
14th Nov 20169:06 amRNSChi-Med Presents Ph I Clinical Data for HMPL-523
1st Nov 20162:57 pmRNSDirector's Share Dealing
31st Oct 20167:00 amRNSJoint Venture - US$59.5m Land Compensation Payment
12th Oct 20167:00 amRNSDirector's Share Dealing
9th Aug 20168:07 amRNSDirector's Share Dealing
2nd Aug 20168:18 amRNSChange of Non-executive Directors
2nd Aug 20167:00 amRNSChi-Med 2016 Interim Results
1st Aug 20167:21 amRNSChi-Med and AstraZeneca to Accelerate Savolitinib
5th Jul 20167:00 amRNSChi-Med to Announce 2016 HY Financial Results
29th Jun 20167:00 amRNSBlocklisting Six Monthly Return
20th Jun 20167:00 amRNSSavolitinib Global Phase II Trial Initiated
15th Jun 20168:09 amRNSAdditional Listing
31st May 20167:00 amRNSTotal Voting Rights
13th May 20167:00 amRNSEnrollment completion of Phase III fruquintinib
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20161:12 pmRNSResults of Annual General Meeting
13th Apr 20164:23 pmRNSExercise of Overallotment Option
31st Mar 20167:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.